Across TCGA pan-cancer cohorts, BMS1P20 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BMS1P20 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BMS1P20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMS1P20 expression acts as an unfavorable survival marker.
HNSC are the cancer types where BMS1P20 Mutation most reproducibly stratifies survival.